SCYNEXIS (Nasdaq: SCYX) granted an inducement equity award to a new Senior Director effective August 24, 2026, under Nasdaq Listing Rule 5635(c)(4). The grant was made pursuant to the company’s 2015 Inducement Award Plan, as amended, to encourage the employee’s acceptance of employment.
The award consists of stock options to purchase 20,000 shares of common stock at an exercise price of $5.26 per share, equal to the closing trading price on the grant date. The options have a ten-year term, with 25% vesting after one year and the remaining shares vesting in equal monthly installments over the following 36 months, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The active S-3 is effective through May 1, 2029 and registers resale shares for selling stockholders...
Analysis
The active S-3 is effective through May 1, 2029 and registers resale shares for selling stockholders. The award's vesting schedule and potential share issuance remain relevant alongside the platform's low short-positioning classification.
Key Figures
Stock options:20,000 sharesExercise price:$5.26 per shareOption term:Ten years+2 more
5 metrics
Stock options20,000 sharesInducement award for new Senior Director
Exercise price$5.26 per shareGrant date August 24, 2026
Option termTen yearsStock options
Initial vestingOne-fourth of sharesOne-year anniversary of commencement date
Remaining vestingThirty-six monthsEqual monthly installments after initial vesting
New Vice President received stock options and restricted stock units.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
SCYX declined after four of five listed news events, including the prior inducement-award announcement, while the Phase 1 study initiation was followed by a positive reaction.
"today announced the grant of an inducement equity award to a new Senior Director"
An inducement equity award is stock or stock-based compensation granted to a new hire as a signing incentive—think of it as a pay package that uses company shares instead of cash. Investors care because it can dilute existing ownership, signal how a company values the new recruit, and align that person’s interests with shareholders; like a signing bonus paid in shares, it affects future share count and management incentives.
nasdaq listing rule 5635(c)(4)regulatory
"approved in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026.The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The award was granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors under Rule 5635(c)(4) for equity grants made to induce new employees to enter into employment with the Company.
The inducement award consists of stock options to purchase 20,000 shares of the Company’s common stock at a per share exercise price of $5.26, the closing trading price on August 24, 2026, the date of grant.The employee’s stock options have a ten-year term, with one-fourth of the shares subject to the options vesting on the one-year anniversary of the employee’s commencement date of August 24, 2026, and the remainder vesting in equal monthly installments for thirty-six months thereafter, subject to the employee’s continued service with the Company.
About SCYNEXIS, Inc.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com
What inducement equity award did SCYNEXIS (SCYX) grant on August 24, 2026?
SCYNEXIS granted stock options to purchase 20,000 shares of common stock on August 24, 2026. According to SCYNEXIS, the options have a $5.26 exercise price, a ten-year term, and were issued as a material inducement for a new Senior Director’s employment.
What is the exercise price and term of the new SCYNEXIS (SCYX) stock options?
The new SCYNEXIS stock options have an exercise price of $5.26 per share and a ten-year term. According to SCYNEXIS, the price equals the August 24, 2026 closing trading price of its common stock, aligning the award’s value with market conditions on the grant date.
How do the SCYNEXIS (SCYX) inducement stock options vest for the new Senior Director?
The inducement stock options vest over four years, with 25% vesting after one year and the rest monthly. According to SCYNEXIS, one-fourth of the shares vest on August 24, 2027, and the remaining shares vest in 36 equal monthly installments, subject to continued employment.
Under which plan and Nasdaq rule were the new SCYX inducement options granted?
The options were granted under the SCYNEXIS 2015 Inducement Award Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4). According to SCYNEXIS, this rule allows equity grants as a material inducement for new employees joining the company outside stockholder-approved plans.
Does the SCYNEXIS (SCYX) inducement award affect existing shareholders through potential dilution?
The inducement award authorizes options on 20,000 shares of SCYNEXIS common stock, which could later be exercised into new shares. According to SCYNEXIS, this grant was specifically made to a new Senior Director as a material inducement to accept employment with the company.
Why did SCYNEXIS (SCYX) use an inducement award for the new Senior Director hire?
SCYNEXIS used the inducement award as a material incentive for the Senior Director to accept employment. According to SCYNEXIS, the grant was structured under its 2015 Inducement Award Plan to align with Nasdaq Listing Rule 5635(c)(4) for new-hire equity incentives.
